ProQR’s Drug Candidate QR-110 for Leber’s Congenital

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ProQR’s Drug Candidate QR-110 for Leber’s Congenital Amaurosis Type 10 Receives EMA and FDA Orphan Drug Designation

LEIDEN, the Netherlands, June 01, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR ) today announced that the company’s investigational drug QR-110 has received orphan drug designation (ODD) from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of Leber’s congenital amaurosis Type 10 (LCA10), the most common cause of genetic blindness in childhood.

ODD in the U.S. and the European Union confers a special status for investigational drugs that are being developed for rare diseases. We expect that development of QR-110 will benefit from tax credits for certain research and a waiver of the NDA application user fee, as well as market exclusivity for seven years in the US for the product and its indication, and ten years in the European Union after market approval.

“LCA10 is a severe genetic eye disease that causes children to go blind in the first few years of life and there is currently no approved therapy available for these patients. We are working on a novel and elegant approach to make a meaningful impact on the lives of patients suffering from LCA10 due to the p.Cys998X mutation,” said Daniel de Boer, Chief Executive Officer of ProQR. “Obtaining orphan drug designations from EMA and FDA for QR-110 highlights the high unmet need in for this disease and are important milestones for our program.”

About LCA10

Leber’s congenital amaurosis is the most common cause of blindness in children and consists of a group of diseases of which LCA Type 10 (LCA10) is one of the more severe forms. LCA10 leads to progressive loss of vision causing most patients to lose their sight in the first few years of life. To date, there are no treatments approved or products in clinical development that treat the underlying cause of the disease. LCA10 is an autosomal recessive disease caused by mutations in the CEP290 gene. The p.Cys998X mutation, the leading cause of LCA10, is a point mutation in the CEP290 gene resulting in an activation of a cryptic splice site. Although prevalence rates vary, we believe approximately 2,000 people in the Western world have LCA10 because of this mutation. The mutated gene and the resulting defective protein lead to dysfunction of the light perceiving cells in the retina (rods and cones), eventually causing blindness.

About QR-110

QR-110 is a first-in-class oligonucleotide, designed to address the underlying cause of LCA10 due to the p.Cys998X mutation. QR-110 is designed to restore wild-type, or normal CEP290 mRNA by binding the pre-mRNA and thereby restoring normal splicing of the pre-mRNA leading to the expression of wild-type CEP 290 protein. QR-110 is designed to be administered through intravitreal injections in the eye.

About ProQR

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis and Leber’s congenital amaurosis. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. Since 2012.

FORWARD-LOOKING STATEMENTS  

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to”, “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding QR-110, including its clinical development and therapeutic potential, and the orphan drug designations for QR-110 for the treatment of LCA10. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, manufacturing processes and facilities, regulatory oversight, product commercialization, intellectual property claims, and the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

ProQR Therapeutics N.V.: Sariette Witte Head of Communications T: +1 213 261 8891 ir@proqr.com

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MERSCO’s Holiday Push Tests Backyard Play Demand in 2026

Updated Category News Views 61

A trampoline sale is not exactly a macroeconomic bellwether, but it does expose a useful little corner of holiday spending: parents buying big, awkward, discretionary stuff that has to earn its space in the yard. MERSCO is joining Amazon’s Black Friday and Cyber Monday window from November 19 through November 30, 2026, with discounts reaching 38% on selected products....

Continue Reading
Markley’s Lowell Campus Turns Data Land Into Arboretum

Updated Category News Views 106

Server halls rarely get credited with restoring a landscape, which is why Markley’s Lowell campus caught my eye. On November 18, 2026, the company said its Lowell data center campus had earned Level I arboretum accreditation from the ArbNet Arboretum Accreditation Program. ArbNet describes itself as the only international accreditation program specifically for arboreta,...

Continue Reading
America's Group Adds Swansea to Its UK Auction Map

Updated Category News Views 117

A Welsh Lane Joins a Larger Road Port Talbot just became a small but telling dot on America's Group's international map. The company has acquired Swansea Motor Vehicle Auction Limited, a long-standing South Wales wholesale and remarketing operation, and plans to run it under the G3 brand. This is not the sort of deal that makes markets levitate. It is the sort that tells...

Continue Reading
Volta M100 Puts Flexibility at Pad Printing's Center

Updated Category News Views 61

A tabletop printer rarely earns a second glance, but the Volta M100 is making a sensible argument: small manufacturers do not need another rigid box that becomes obsolete the minute a job changes. Boston Industrial Solutions has introduced the Volta M100 as a pad-printing machine built around adjustability, operator convenience, and software that can be upgraded as...

Continue Reading
Lummus-Versalis Deal Adds Nine Elastomer Technologies

Updated Category News Views 104

Nine elastomer technologies do not make a flashy headline, yet this is the sort of chemical-industry move that can matter long after the applause dies down. Lummus Technology and Versalis have expanded their partnership to cover nine elastomer technologies. That is the disclosed fact, and it is meaningful on its own. The release does not lay out contract value, duration,...

Continue Reading
Workday GO for Financials Targets the Messy Middle

Updated Category News Views 182

Spreadsheets rarely die gracefully; they get buried under approvals, reconciliations, and the frantic scavenger hunt before an audit. Workday is aiming straight at that unpleasant moment with Workday GO for Financials, announced November 18 at Workday Rising EMEA in Barcelona. The pitch is not terribly romantic, thank goodness. It is a simpler way for growing companies to...

Continue Reading
RazorMetrics' Fast 500 Run Merits a Harder Investor Look

Updated Category News Views 66

A 4,488% growth figure can make even a seasoned skeptic sit upright. RazorMetrics landed at No. 20 on Deloitte's 2026 Technology Fast 500 after ranking No. 12 in 2025, and it again took the top Texas slot. That is serious momentum for an Austin company working on one of healthcare's most stubborn expenses: prescription drugs. Still, this is healthcare cost containment,...

Continue Reading
Mantle's Japan Listing Puts $MNT Through a Real Test

Updated Category News Views 173

Japan's crypto gatekeepers just handed Mantle a key, not a crown. The November 18 listing of $MNT on GMO Coin is a meaningful operational win because getting onto a Japanese centralized exchange is not the usual loose-change exercise seen in friendlier jurisdictions. Mantle cleared a review process involving GMO Coin and the Japan Virtual and Crypto Assets Exchange...

Continue Reading
Anycubic Pushes Toward a Smoother 3D Printing Ecosystem

Updated Category News Views 125

Friction Is the Enemy in Consumer 3D Printing A printer that makes a beautiful object only after three failed attempts is not a consumer product; it is a weekend argument with plastic. That is the useful lens for Anycubic's Formnext 2026 showing in Frankfurt on November 18. The company is not merely rolling out FDM and resin machines at Booth F01 in Hall 12.0. It is...

Continue Reading
Three Deal Reviews Put Merger Terms Under Scrutiny

Updated Category News Views 140

Three proposed transactions just picked up the sort of legal glare boards hate seeing. A shareholder-rights firm, Halper Sadeh, said on November 18, 2026 that it is investigating whether the deals involving Greenland Energy, Rapid Micro Biosystems and Aytu BioPharma may involve federal securities-law violations or breaches of fiduciary duty. That is an allegation worth...

Continue Reading

Top 5 Most Recently Viewed Articles

Ford Motor Company Faces Legal Challenges: Key Insights

Updated Category News Views 119

Understanding the Legal Landscape for Ford Motor Company As investors navigate the intricate world of stock ownership, recent events surrounding Ford Motor Company have raised eyebrows. The company currently finds itself at the center of a class action lawsuit involving shareholders who acquired stock during a specific period. Class Action Overview and Important Dates...

Continue Reading
Transforming the Specialty Fats and Oils Industry for Success

Updated Category News Views 188

A Deep Dive into the Specialty Fats and Oils Market The landscape of the specialty fats and oils market is rapidly transforming, growing from its valuation of US$ 16.12 billion in the preceding year to a staggering US$ 31.69 billion by 2033, marking a robust CAGR of 7.8% during the next financial stretch. This growth signals a significant shift in industry dynamics and...

Continue Reading
C3.ai: Analyzing Current Trends in the Options Market

Updated Category News Views 241

Current Sentiment on C3.ai Recently, well-known investors—often referred to as whales—have taken a decidedly negative stance towards C3.ai. This growing skepticism stems from the history of options involving the company's stock. An analysis of C3.ai's (AI) trading patterns uncovered nine notable trades. Digging deeper into these transactions shows that only 22% of...

Continue Reading
CytomX Therapeutics Completes $100 Million Stock Offering

Updated Category News Views 315

CytomX Therapeutics Completes $100 Million Stock Offering CytomX Therapeutics, Inc. (NASDAQ: CTMX), based in South San Francisco, has just announced the pricing of an extensive stock offering. The company is set to offer 76,923,076 shares of its common stock at a price of $1.30 per share. This significant transaction aims to raise approximately $100 million and is being...

Continue Reading
Wall Street's Bullish Coverage Initiation Highlights for NKE and Others

Updated Category News Views 120

Wall Street Analysts Initiate Coverage on Key Stocks In a dynamic market landscape, top analysts have recently adjusted their ratings on several prominent companies. Their insights provide a glimpse into potential future performance for investors. Today, we spotlight these analyst ratings and what they mean for some notable stocks. NIKE, Inc. (NKE) Coverage by Needham...

Continue Reading